Herpes zoster vaccination program in the NHS records low coverage in the elderly

Serviço Nacional of Saúde of Essa situation worries experts, who emphasize the importance of immunization to prevent serious complications associated with the disease.
The Shingrix vaccine, offered free of charge, is aimed at individuals aged 65 or over, in addition to specific groups with severe immunosuppression from the age of 18 onwards. The program, expanded in September 2023 and updated in 2025, aims to protect vulnerable populations from a condition that can cause severe pain and long-lasting effects.
Official reports indicate that, by October 2025, only 42.1% of people who turned 66 had received the first dose, while among those aged 71, coverage reached 53.5%. Esses numbers highlight the need for more effective campaigns to increase participation.
Expanded eligibility
The NHS shingles vaccination program has undergone significant adjustments in recent years to include more age groups and health conditions. Inicialmente focused on seniors aged 70 and over, the expansion allowed adults aged 65 and over to be incorporated from September 2023.
This change reflects recommendations from Comitê Conjunto of Vacinação and Imunização, which identified elevated risks in younger groups with compromised immune systems. The vaccine is administered in two doses, six to 12 months apart, and is available in general practices or via the NHS website.

Current coverage
Data released by Agência of Segurança Sanitária of Reino Unido show variations in adherence by age group. Para immunocompetent individuals who turn 65 years old, coverage of the first dose is around 42%, while the second dose is even lower.
Among those turning 70, the rates are slightly higher, but still insufficient to guarantee collective protection. Autoridades note that factors such as lack of awareness and limited access to consultations contribute to these results.
Benefits of immunization
The Shingrix vaccine demonstrates high efficacy in preventing herpes zoster, reducing the risk of developing the disease in healthy adults by more than 90%. Estudos clinicians confirm that it also reduces the incidence of post-herpetic neuralgia, a complication that causes persistent chronic pain.
Immunosuppressed patients, including those being treated for cancer or with autoimmune conditions, especially benefit, as the varicella-zoster virus can reactivate more easily in these cases. Immunization not only prevents individual outbreaks, but contributes to reducing infection-related hospitalizations.
Risks of the disease
Herpes zoster arises from the reactivation of the varicella virus, the same virus responsible for chickenpox in childhood. Sintomas include tingling skin, severe pain, fever, and rashes that usually affect the trunk or face.
In the elderly and immunosuppressed, the condition can develop into complications such as secondary infections or neurological problems. Relatos doctors indicate that around 20% of cases result in prolonged pain, impacting mobility and daily quality of life.
Expansion to vulnerable groups
From September 2025, the NHS has extended eligibility to all adults with severe immunosuppression aged 18 and over, with no upper age limit. Essa measure meets updated guidance that recognizes increased risks in younger populations with chronic conditions.
Health professionals recommend that these individuals be prioritized, with vaccination ideally started one month before immunosuppressive treatments. The initiative aims to cover gaps identified in previous programs, where the Zostavax vaccine was replaced by the Shingrix due to its greater efficacy.
Implementation occurs in phases to manage demand on health services. Clínicas locations and pharmacies participate in distribution, facilitating access in urban and rural regions.
Adherence Increasing Strategies
NHS authorities plan educational campaigns to inform about the benefits of the vaccine and dispel common doubts. Parcerias with community organizations and the use of digital reminders via health apps are part of these efforts.
Studies indicate that interventions such as pharmaceutical consultations without the need for prior scheduling increase vaccination rates. In regions like Inglaterra, where annual coverage is monitored, adjustments based on real data guide future actions.
Impact on public health
Herpes zoster affects thousands of people annually in the Reino Unido, with estimates of up to 50 thousand cases in adults over 50 years of age. Mass vaccination could reduce this number significantly, relieving pressure on the healthcare system.
Annual coverage reports, such as the one published in February 2026, serve as the basis for ongoing assessments. Especialistas highlight that current low adherence can lead to spikes in incidence, especially in aging populations.
Recommendations for patients
Eligible individuals should contact their GP to book their vaccination, which is available free of charge on the NHS. Para those with initial symptoms of shingles, pharmacies now offer prescription medications without a doctor’s consultation, speeding up treatment.
Guidelines include monitoring for mild side effects, such as pain at the injection site or fatigue, which generally resolve within a few days. Adherence to the two-dose schedule is essential for maximum protection.
Continuous monitoring
Agência of Segurança Sanitária of Reino Unido publishes periodic reports on vaccination coverage, with data collected from September 2024 to August 2025 showing stable but lower than expected trends. Esses documents guide adjustments to the program, ensuring that resources are allocated efficiently.
Comparisons with previous years reveal gradual improvements in adherence among immunosuppressed groups, thanks to the 2025 expansion. However, challenges persist in areas with less access to health services, requiring localized interventions.
Long-term perspectives
The NHS shingles vaccination program is designed to extend over the decade, incorporating more cohorts as resources allow. Avaliações of Comitê Conjunto of Vacinação and Imunização continue to influence policy, based on up-to-date scientific evidence.
Integration with other immunization programs, such as against influenza and pneumococcus, optimizes logistics and increases convenience for patients. Essa holistic approach aims to increase overall vaccine coverage in adults.
Technical details of the vaccine
Shingrix is a non-live recombinant vaccine, safe for use in immunosuppressed people, unlike previous options. Sua composition includes antigens that stimulate a robust immune response, with effectiveness maintained for years.
Clinical tests involved thousands of participants, confirming its tolerability in different age groups. The NHS provides detailed guidance on its website, including eligibility criteria and administration procedures.
Regional experiences
In Inglaterra, dedicated shingles vaccination clinics operate in health centers, such as in Lincolnshire, with sessions scheduled for March 2026. Essas local initiatives complement the national effort by reaching specific communities.
In Escócia, the reduction of the minimum age to 60 years old occurs in phases, prioritizing efficiency in vaccine delivery. Diferenças regions in the NHS emphasize adaptation to local needs, maintaining uniform quality standards.
Additional risk factors
Factors such as advanced age and a history of chickenpox increase susceptibility to shingles. Pacientes with conditions such as diabetes or rheumatoid arthritis face greater risks, making vaccination a crucial preventive tool.
Epidemiological studies indicate that stress and certain medications can trigger viral reactivation. Conscientização on these elements helps in early identification and promotion of immunization.
Support for healthcare professionals
Technical guides updated by the NHS England guide general practices in administering the vaccine, including identifying eligible patients. Continuous Treinamentos ensure teams are prepared to respond to queries and manage inventory.
Collaborations with medical associations, such as Sociedade Britânica of Torácica, provide specific recommendations for patients with respiratory or kidney conditions. Essa support network strengthens program implementation.
Serviço Nacional of Saúde of Essa statistics reflect logistical and awareness challenges, but also opportunities for more targeted interventions, such as digital campaigns and partnerships with community pharmacies to facilitate access.
Furthermore, the expansion to adults aged 18 and over with severe immunosuppression, implemented in September 2025, is already showing signs of increasing demand, although adherence to the second dose remains low at 16.2%, requiring strategies to reinforce compliance with the complete regimen. Especialistas note that integration with other vaccine programs could increase these rates, reducing barriers for patients.
Regulatory updates
Livro Verde guidelines on shingles, updated by the British government, define precise criteria for severe immunosuppression, including patients undergoing chemotherapy or transplants. Essas standards ensure that vaccination is prioritized based on medical evidence.
Industrial partnerships
Companies such as GSK collaborate with the NHS to distribute Shingrix, providing supplies and educational materials. Essas alliances accelerate the expansion of the program, maintaining a focus on accessibility.






